CDEX’s Medical Patent Offers Industry Increased Security

Send Email

medical patent CDEXCDEX, Inc. demonstrated two chemical detection innovations in their medical patent portfolio at a recent trade show in Las Vegas, NV (CNNMoney, December 18, 2007). The two patent pending devices are ValiMed (TM) Medical Validation System and Meth Scanner (TM), both of which were duly received for their advanced ability to determine the chemical composition of medication (ValiMed) or the presence of narcotics (Meth Scanner).


ValiMed, which is credited with "saving lives in hospitals across the nation," determines whether the medication inside the package–and not just the label–contains the medication to which it claims. Furthermore, it is easy to use with a simple declaration of "validated" or "not validated." I can picture the trade show audience of national and international hospital executives, pharmacists, and other industry representatives nodding their heads in approval at as this adds a considerable safety measure, which has broad implications for patients as well as financial bottom lines.


Meth Scanner is a patent pending medical device that is a useful narcotics detector inside and outside of hospitals. As a complement to this scanner, CDEX also unveiled their new Fentanyl Validation System, which strengthens the procedures for preventing "narcotic diversion in medical facilities." Meth Scanner is one in a wide portfolio of patented/patent pending innovations designed to determine the presence of narcotics, including devices that can integrate their detection technology into medical products that already exist.


It’s hard to imagine a broader category for medical innovation than that of safety. CDEX has certainly made a big business of this, and maybe you can, too.

Trackbacks (0) Links to blogs that reference this article Trackback URL
Send To A Friend Use this form to send this entry to a friend via email.